Ajanta Pharma Ltd (AJANTPHARM)
🎯 Key Takeaways
- Ajanta Pharma is in a strong growth phase, characterized by consistent double-digit revenue and profit expansion, robust margins, and a strategic focus on high-margin segments like Branded Generics and international markets. Management is prioritizing shareholder returns through dividends while maintaining a conservative capital structure, supported by healthy cash flows and minimal leverage.
- Revenue grew 14.4% QoQ to ₹1,626 in Q1FY27.
- ⚠️ Over-reliance on Branded Generics (66% of revenue) exposes the company to margin pressure from pricing competition or regulatory changes in key market
📖 The Story
Ajanta Pharma is in a strong growth phase, characterized by consistent double-digit revenue and profit expansion, robust margins, and a strategic focus on high-margin segments like Branded Generics and international markets. Management is prioritizing shareholder returns through dividends while maintaining a conservative capital structure, supported by healthy cash flows and minimal leverage.
📰 What's Happening
In Q1 FY27, Ajanta Pharma delivered 25% revenue growth to Rs 1,626 crore and 31% PAT growth to Rs 334 crore, driven by strong performance in Branded Generics (66% of revenue), US Generics (57% growth), and Africa markets. The Board approved a first interim dividend of Rs 32 per share (Rs 400 crore total) for FY27, payable after 18 August 2026, with a record date of 5 August 2026. Management highlighted robust R&D, global market presence, and operational efficiency, with the earnings conference call scheduled for 30 July 2026 to discuss results.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 1,354 | 1,375 | 1,422 | 1,626 |
| Operating Profit | 285 | 339 | 288 | 379 |
| OPM % | 21.0% | 24.6% | 20.3% | 23.3% |
| Net Profit | 260 | 274 | 267 | 334 |
| EPS | ₹20.83 | ₹21.91 | ₹21.35 | ₹26.75 |
The company is demonstrating accelerating profitability, with operating margins expanding to 23.3% in Q1 FY27 from 20.3% in the previous quarter, and net profit growth outpacing revenue growth. This margin expansion reflects improved operational efficiency and a favorable product mix, particularly in higher-margin Branded Generics and international segments. The consistent quarter-on-quarter growth in revenue, operating profit, and net profit underscores management’s ability to execute on growth initiatives while maintaining cost discipline.
🔮 Management Outlook & What's Next
No forward guidance was provided in the latest filings regarding future revenue, profit, or margin expectations. Management has not articulated specific targets or projections for upcoming quarters, focusing instead on reporting past performance and operational achievements. The absence of forward-looking commentary suggests a conservative approach to guidance, with emphasis on execution rather than prediction.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 25 | 25 | 25 | 25 |
| Reserves | 3,652 | 3,765 | 4,290 | 4,502 |
| Borrowings | 33 | 47 | 246 | 212 |
| Total Liabilities | 4,791 | 5,015 | 5,672 | 6,155 |
| Fixed Assets | 1,438 | 1,716 | 1,832 | 1,867 |
| Investments | 702 | 464 | 874 | 588 |
| Total Assets | 4,791 | 5,015 | 5,672 | 6,155 |
The balance sheet reflects a strong financial position with equity of Rs 25 crore and reserves of Rs 4,502 crore as of March 2026, indicating substantial capital reserves. Borrowings remain low at Rs 212 crore, down from Rs 47 crore a year ago, signaling a deleveraging trend. Total assets have grown steadily to Rs 6,155 crore, supporting expansion without over-reliance on debt. This conservative capital structure enables strategic investments and dividend payouts without financial strain.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2026 |
|---|---|
| Operating | +529 |
| Investing | -429 |
| Financing | -168 |
| Net Cash Flow | -68 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 66.3% | 66.3% | 66.3% | 63.5% |
| FII | 8.5% | 8.0% | 8.3% | 7.7% |
| DII | 17.9% | 18.6% | 18.4% | 21.8% |
| Public | 6.5% | 6.4% | 6.3% | 6.3% |
| # Shareholders | 67,785 | 65,409 | 67,955 | 65,296 |
Promoter holding has remained stable at 66.25% over the last four quarters, indicating no dilution or stake reduction. Institutional investors (FII) have slightly increased their stake from 7.98% to 8.26%, while DII holdings have grown from 17.9% to 21.8%, suggesting growing confidence among foreign and domestic institutional investors. The rising number of public shareholders (from 65,409 to 67,955) reflects broadening retail interest. No significant selling by promoters or institutions has been observed.
⚖️ Peer Comparison — Pharmaceuticals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| SUNPHARMA | 4.42 L Cr | 36.5 | 18.7% | 14.6% | 0.05 |
| DIVISLAB | 2.48 L Cr | 84.6 | 23.0% | 17.4% | 0.00 |
| TORNTPHARM | 1.89 L Cr | 79.4 | 15.1% | 25.7% | 1.76 |
| ZYDUSLIFE | 1.12 L Cr | 24.9 | 16.8% | 16.6% | 0.43 |
| CIPLA | 1.10 L Cr | 32.7 | 13.2% | 9.8% | 0.01 |
| LAURUSLABS | 1.06 L Cr | 97.3 | 20.8% | 20.6% | 0.45 |
| DRREDDY | 96,906 | 30.0 | 10.1% | 8.4% | 0.17 |
| AUROPHARMA | 96,402 | 26.2 | 12.8% | 9.8% | 0.20 |
| LUPIN | 95,836 | 16.9 | 27.9% | 24.7% | 0.26 |
| MANKIND | 94,039 | 46.0 | 13.9% | 12.7% | 0.38 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1. Over-reliance on Branded Generics (66% of revenue) exposes the company to margin pressure from pricing competition or regulatory changes in key markets like India and Africa. 2. US Generic growth, while strong at 57%, is subject to regulatory hurdles and patent expiries, making it volatile. 3. Low free cash flow (Net -₹68 crore in Q1 FY27 due to investing and financing outflows) raises concerns about sustainability of dividend payouts if operating performance slows. 4. High promoter concentration (66.25%) may limit liquidity and increase governance scrutiny if market sentiment shifts.
📋 Recent Filings
-
Announcement 31 August 2026Ajanta Pharma announced its schedule for upcoming investor meetings with Jefferies India Forum on September 16, 2026, and PL Capital Mid & Small Cap C...
-
🔴 Insider Trading 27 August 2026Ajanta Pharma Ltd disclosed that promoter group entities including Yogesh Agrawal Trust, Rajesh Agrawal Trust, and Ravi Agrawal Trust released pledges...
-
Announcement 5 August 2026Ajanta Pharma announced its schedule for analyst and institutional investor meetings in August 2026, including one-on-one sessions at the Nuvama India...
-
Announcement 3 August 2026Ajanta Pharma announced that a written transcript of its Q1 FY26 earnings call held on July 30, 2026, is now available on its website, providing inves...
-
Announcement 30 July 2026Ajanta Pharma announced that its Nomination and Remuneration Committee allotted 23,400 equity shares of Rs 2 each upon option exercise, increasing pai...
-
🔴 Corporate Action 30 July 2026Ajanta Pharma announced a 1st interim dividend of Rs. 32 per share (Rs. 400 cr. total) for FY27, payable after 18 August 2026, with record date on 5 A...
-
🟡 Board Meeting 30 July 2026Ajanta Pharma announced its Q1 FY2027 results on 30 July 2026, reporting 25% revenue growth to Rs 1,626 crore and 31% PAT growth to Rs 334 crore. The ...
-
Announcement 30 July 2026Ajanta Pharma announced that an audio recording of its earnings call held on 30 July 2026 is now available on its website, with a transcript to follow...
-
🔴 Corporate Action 30 July 2026Ajanta Pharma announced that August 5, 2026 will be the record date for determining shareholders eligible to receive its first interim dividend, as re...
-
🔴 Financial Results 21 July 2026Ajanta Pharma announced a revised timing for its Q1 FY2027 earnings conference call, now scheduled for 4:15 p.m. IST on July 30, 2026, following the b...
🧠 Analyst's Read
Ajanta Pharma is executing a disciplined growth strategy with strong margins and consistent financial performance, supported by a healthy balance sheet and growing institutional interest. The key watchpoints are sustaining margin expansion, managing regulatory risks in US and African markets, and ensuring dividend payouts remain sustainable amid capital allocation priorities. Investors should monitor upcoming earnings calls for operational updates and potential shifts in growth trajectory.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-13.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when AJANTPHARM files new disclosures
Track AJANTPHARM filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track AJANTPHARM — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research
About · Privacy Policy · Terms of Service · Pricing
Today's Announcements · Screener · Insights · AI Chat
Data provided by CMOTS Internet Technologies Pvt Ltd